IsoRay

IsoRay ROE

Delisted

The Return on Equity (ROE) of IsoRay (ISR) as of Nov 4, 2026 is -11.67 %. In the previous year, Return on Equity (ROE) was -4.74 % — a change of 146.12% (lower).

ROE

-11.67 %

YoY

146.12%

Last updated:

In 2022, IsoRay's return on equity (ROE) was -11.67 %, a 146.12% increase from the -4.74 % ROE in the previous year.

The IsoRay ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
-17.71 USD
Jan 1, 2016
-28.72 USD
Jan 1, 2017
-58.12 USD
Jan 1, 2018
-133.20 USD
Jan 1, 2019
-63.15 USD
Jan 1, 2020
-57.12 USD
Jan 1, 2021
-4.74 USD
Jan 1, 2022
-11.67 USD
The IsoRay ROE history
YEARROEYoY
-11.67 %+146.12%
-4.74 %-91.70%
-57.12 %-9.55%
-63.15 %-52.59%
-133.20 %+129.18%
-58.12 %+102.35%
-28.72 %+62.16%
-17.71 %-28.80%
-24.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IsoRay Stock analysis

What does IsoRay do? The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. IsoRay is one of the most popular companies on Eulerpool.

ROE Details

Decoding IsoRay's Return on Equity (ROE)

IsoRay's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing IsoRay's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

IsoRay's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in IsoRay’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about IsoRay stock

Return on Equity (ROE) of IsoRay is -11.67 % in 2022.

Return on Equity (ROE) of IsoRay changed from -4.74 % to -11.67 %, representing a 146.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) IsoRay since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s IsoRay with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — IsoRay

All Key Metrics — IsoRay